rosiglitazone has been researched along with Carotid Artery Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J; Wang, LN | 1 |
| Li, D; Liu, K; Wang, T; Xu, R; Zhao, D; Zhu, Z | 1 |
| Bosch, J; Dagenais, GR; Diaz, R; Gerstein, HC; Lonn, EM; Mohan, V; Sheridan, P; Smith, S; Yusuf, S | 1 |
| Chan, CF; Crowe, LA; Johnston, DG; Keenan, NG; Pennell, DJ; Varghese, A; Yee, MS | 1 |
| Fisher, M | 1 |
| Chinetti, G; Fruchart, JC; Staels, B; Zawadski, C | 1 |
| Kaposzta, Z; Kaski, JC; Markus, HS; Sidhu, JS | 1 |
| Baker, DL; Balazs, L; Bittman, R; Byun, HS; Johnson, LR; Makarova, N; Marathe, GK; McIntyre, TM; Prestwich, GD; Tigyi, G; Xu, Y; Yasuda, S; Zhang, C | 1 |
| Fan, L; Forudi, F; Lincoff, AM; Penn, MS; Qu, W; Schmidt, AM; Topol, EJ; Wang, K; Zhang, M; Zhou, X; Zhou, Z | 1 |
| Baldi, A; Cacciapuoti, F; Carbonara, O; Coppola, L; Crescenzi, B; D'Amico, M; Di Filippo, C; Ferraraccio, F; Marfella, R; Nicoletti, GF; Paolisso, G; Portoghese, M; Rossi, F; Rossiello, R; Sangiuolo, P; Sasso, FC; Siniscalchi, M; Verza, M | 1 |
| Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A | 1 |
2 review(s) available for rosiglitazone and Carotid Artery Diseases
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin | 2017 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance | 2009 |
4 trial(s) available for rosiglitazone and Carotid Artery Diseases
| Article | Year |
|---|---|
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Fasting; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tunica Intima; Ultrasonography | 2009 |
Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Imaging, Three-Dimensional; Magnetic Resonance Angiography; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome | 2009 |
Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Common; Cohort Studies; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Insulin Resistance; Lipids; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Ultrasonography; Weight Gain | 2004 |
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima | 2007 |
5 other study(ies) available for rosiglitazone and Carotid Artery Diseases
| Article | Year |
|---|---|
Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ.
Topics: Benzamides; Carotid Artery Diseases; Cell Differentiation; Cells, Cultured; Chemotaxis; Combined Modality Therapy; Depression, Chemical; Diabetes Mellitus, Type 2; Down-Regulation; Endarterectomy, Carotid; Gene Expression Regulation; Humans; Macrophages; Pioglitazone; PPAR alpha; PPAR gamma; Pyridines; Receptors, CXCR; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2015 |
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.
Topics: Carotid Artery Diseases; Cells, Cultured; DNA-Binding Proteins; Endothelium, Vascular; Gene Expression Regulation; Humans; Liver X Receptors; Macrophages; Orphan Nuclear Receptors; Pyrimidines; Receptors, Adiponectin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Lysophosphatidic acid induces neointima formation through PPARgamma activation.
Topics: Analysis of Variance; Anilides; Animals; Arteriosclerosis; Calmodulin-Binding Proteins; Carotid Artery Diseases; CD36 Antigens; Cells, Cultured; Disease Models, Animal; DNA Primers; Growth Substances; Ligands; Lipoproteins, LDL; Lysophospholipids; Male; Muscle, Smooth; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Time Factors; Transcription Factors | 2004 |
Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
Topics: Animals; Blood Glucose; Carotid Artery Diseases; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Down-Regulation; Endothelial Cells; Glycation End Products, Advanced; Insulin; Lipids; PPAR gamma; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2006 |
Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment.
Topics: Aged; Carotid Artery Diseases; Female; Humans; Inflammation; Macrophages; Male; Proteasome Endopeptidase Complex; Rosiglitazone; Thiazolidinediones; Ubiquitin-Protein Ligase Complexes | 2006 |